Mucosal damage and neutropenia are required for Candida albicans dissemination

PLoS Pathogens

Volumn 4, Issue 2, 2008, Pages

  Koh, Andrew Y ^a,b,c   Köhler, Julia R ^b   Coggshall, Kathleen T ^a   Van Rooijen, Nico ^d   Pier, Gerald B ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b BOSTON CHILDREN S HOSPITAL   (United States)

^c DANA FARBER CANCER INSTITUTE   (United States)

^d VU UNIVERSITY AMSTERDAM   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; CYCLOPHOSPHAMIDE; ANTIINFECTIVE AGENT;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CANDIDA ALBICANS; CHEMOTHERAPY; FEMALE; FUNGAL COLONIZATION; FUNGEMIA; FUNGUS HYPHAE; GASTROINTESTINAL MUCOSA; IMMUNE DEFICIENCY; INNATE IMMUNITY; INTESTINE FLORA; LYMPHOCYTOPENIA; MACROPHAGE; MORTALITY; MOUSE; MUCOSAL DISEASE; MYCOSIS; NEUTROPENIA; NEUTROPHIL; NONHUMAN; YEAST; ANIMAL; BACTERIAL TRANSLOCATION; C3H MOUSE; CANDIDIASIS; CHEMICALLY INDUCED DISORDER; DISEASE MODEL; DRUG EFFECT; GASTROINTESTINAL TRACT; GENE SILENCING; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LONGEVITY; MICROBIOLOGY; MOUSE MUTANT; MUCOSA; PATHOGENICITY; PATHOLOGY;

CANDIDA ALBICANS;

ANIMALS; ANTI-BACTERIAL AGENTS; BACTERIAL TRANSLOCATION; CANDIDA ALBICANS; CANDIDIASIS; CYCLOPHOSPHAMIDE; DISEASE MODELS, ANIMAL; FEMALE; GASTROINTESTINAL TRACT; GENE SILENCING; IMMUNOSUPPRESSION; LONGEVITY; MICE; MICE, INBRED C3H; MICE, KNOCKOUT; MUCOUS MEMBRANE; NEUTROPENIA;

EID: 40349102094     PISSN: 15537366     EISSN: 15537374     Source Type: Journal    
DOI: 10.1371/journal.ppat.0040035     Document Type: Article

References (64)

1. DiNubile MJ, Hille D, Sable CA, Kartsonis NA (2005) Invasive candidiasis in cancer patients: Observations from a randomized clinical trial. J Infect 50: 443-449.
2. Paulus SC, van Saene HK, Hemsworth S, Hughes J, Ng A, et al. (2005) A prospective study of septicaemia on a paediatric oncology unit: A three-year experience at The Royal Liverpool Children's Hospital, Alder Hey, UK. Eur J Cancer 41: 2132-2140.
3. Wilson LS, Reyes CM, Stolpman M, Speckman J, Allen K, et al. (2002) The direct cost and incidence of systemic fungal infections. Value Health 5: 26-34.
4. Gudlaugsson O, Gillespie S, Lee K, Vande Berg J, Hu J, et al. (2003) Attributable mortality of nosocomial candidemia, revisited. Clin Infect Dis 37: 1172-1177.
5. Wang SM, Yang YJ, Chen JS, Lin HC, Chi CY, et al. (2005) Invasive fungal infections in pediatric patients with leukemia: emphasis on pulmonary and dermatological manifestations. Acta Paediatr Taiwan 46: 149-155.
6. Rosen GP, Nielsen K, Glenn S, Abelson J, Deville J, et al. (2005) Invasive fungal infections in pediatric oncology patients: 11-year experience at a single institution. J Pediatr Hematol Oncol 27: 135-140.
7. Bodey G, Bueltmann B, Duguid W, Gibbs D, Hanak H, et al. (1992) Fungal infections in cancer patients: An international autopsy survey. Eur J Clin Microbiol Infect Dis 11: 99-109.
8. Groll AH, Shah PM, Mentzel C, Schneider M, Just-Nuebling G, et al. (1996) Trends in the postmortem epidemiology of invasive fungal infections at a university hospital. J Infect 33: 23-32.
9. Pizzo PA, Poplack DG (2002) Principles and practice of pediatric oncology. Philadelphia: Lippincott Williams & Wilkins. 1,692 p.
10. Berg RD (1999) Bacterial translocation from the gastrointestinal tract. Adv Exp Med Biol 473: 11-30.
11. Shoham S, Levitz SM (2005) The immune response to fungal infections. Br J Haematol 129: 569-582.
12. Pasqualotto AC, Nedel WL, Machado TS, Severo LC (2006) Risk factors and outcome for nosocomial breakthrough candidaemia. J Infect 52: 216-222.
13. Andes D, Marchillo K, Stamstad T, Conklin R (2003) In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob Agents Chemother 47: 3165-3169.
14. Coligan JE (2001) Current protocols in immunology. New York: Wiley.
15. Barnes JL, Osgood RW, Lee JC, King RD, Stein JH (1983) Host-parasite interactions in the pathogenesis of experimental renal candidiasis. Lab Invest 49: 460-467.
16. Papadimitriou JM, Ashman RB (1986) The pathogenesis of acute systemic candidiasis in a susceptible inbred mouse strain. J Pathol 150: 257-265.
17. Bader T, Schroppel K, Bentink S, Agabian N, Kohler G, et al. (2006) Role of calcineurin in stress resistance, morphogenesis, and virulence of a Candida albicans wild-type strain. Infect Immun 74: 4366-4369.
18. Jackson BE, Mitchell BM, Wilhelmus KR (2007) Corneal virulence of Candida albicans strains deficient in Tup1-regulated genes. Invest Ophthalmol Vis Sci 48: 2535-2539.
19. Pitarch A, Diez-Orejas R, Molero G, Pardo M, Sanchez M, et al. (2001) Analysis of the serologic response to systemic Candida albicans infection in a murine model. Proteomics 1: 550-559.
20. Westwater C, Schofield DA, Nicholas PJ, Paulling EE, Balish E (2007) Candida glabrata and Candida albicans; dissimilar tissue tropism and infectivity in a gnotobiotic model of mucosal candidiasis. FEMS Immunol Med Microbiol 51: 134-139.
21. Fonzi WA, Irwin MY (1993) Isogenic strain construction and gene mapping in Candida albicans. Genetics 134: 717-728.
22. Lo HJ, Kohler JR, DiDomenico B, Loebenberg D, Cacciapuoti A, et al. (1997) Nonfilamentous C. albicans mutants are avirulent. Cell 90: 939-949.
23. Braun BR, Johnson AD (1997) Control of filament formation in Candida albicans by the transcriptional repressor TUP1. Science 277: 105-109.
24. Flynn PM, Marina NM, Rivera GK, Hughes WT (1993) Candida tropicalis infections in children with leukemia. Leuk Lymphoma 10: 369-376.
25. Richet HM, Andremont A, Tancrede C, Pico JL, Jarvis WR (1991) Risk factors for candidemia in patients with acute lymphocytic leukemia. Rev Infect Dis 13: 211-215.
26. Nucci M, Anaissie E (2001) Revisiting the source of candidemia: Skin or gut? Clin Infect Dis 33: 1959-1967.
27. Mellado E, Cuenca-Estrella M, Regadera J, Gonzalez M, Diaz-Guerra TM, et al. (2000) Sustained gastrointestinal colonization and systemic dissemination by Candida albicans, Candida tropicalis and Candida parapsilosis in adult mice. Diagn Microbiol Infect Dis 38: 21-28.
28. de Repentigny L, Phaneuf M, Mathieu LG (1992) Gastrointestinal colonization and systemic dissemination by Candida albicans and Candida tropicalis in intact and immunocompromised mice. Infect Immun 60: 4907-4914.
29. Takahashi K, Kita E, Konishi M, Yoshimoto E, Mikasa K, et al. (2003) Translocation model of Candida albicans in DBA-2/J mice with protein calorie malnutrition mimics hematogenous candidiasis in humans. Microb Pathog 35: 179-187.
30. Cole GT, Lynn KT, Seshan KR, Pope LM (1989) Gastrointestinal and systemic candidosis in immunocompromised mice. J Med Vet Mycol 27: 363-380.
31. Wiesner SM, Jechorek RP, Garni RM, Bendel CM, Wells CL (2001) Gastrointestinal colonization by Candida albicans mutant strains in antibiotic-treated mice. Clin Diagn Lab Immunol 8: 192-195.
32. Clemons KV, Gonzalez GM, Singh G, Imai J, Espiritu M, et al. (2006) Development of an orogastrointestinal mucosal model of candidiasis with dissemination to visceral organs. Antimicrob Agents Chemother 50: 2650-2657.
33. Samonis G, Anaissie EJ, Rosenbaum B, Bodey GP (1990) A model of sustained gastrointestinal colonization by Candida albicans in healthy adult mice. Infect Immun 58: 1514-1517.
34. Wells CL, Maddaus MA, Reynolds CM, Jechorek RP, Simmons RL (1987) Role of anaerobic flora in the translocation of aerobic and facultatively anaerobic intestinal bacteria. Infect Immun 55: 2689-2694.
35. Koh AY, Priebe GP, Pier GB (2005) Virulence of Pseudomonas aeruginosa in a murine model of gastrointestinal colonization and dissemination in neutropenia. Infect Immun 73: 2262-2272.
36. Mahler M, Bristol IJ, Leiter EH, Workman AE, Birkenmeier EH, et al. (1998) Differential susceptibility of inbred mouse strains to dextran sulfate sodium-induced colitis. Am J Physiol 274: G544-G551.
37. Fulurija A, Ashman RB, Papadimitriou JM (1996) Neutrophil depletion increases susceptibility to systemic and vaginal candidiasis in mice, and reveals differences between brain and kidney in mechanisms of host resistance. Microbiology 142: 3487-3496.
38. Ashman RB, Papadimitriou JM, Fulurija A, Drysdale KE, Farah CS, et al. (2003) Role of complement C5 and T lymphocytes in pathogenesis of disseminated and mucosal candidiasis in susceptible DBA/2 mice. Microb Pathog 34: 103-113.
39. Cenci E, Romani L, Vecchiarelli A, Puccetti P, Bistoni F (1989) Role of L3T4+ lymphocytes in protective immunity to systemic Candida albicans infection in mice. Infect Immun 57: 3581-3587.
40. Marquis M, Lewandowski D, Dugas V, Aumont F, Senechal S, et al. (2006) CD8+ T cells but not polymorphonuclear leukocytes are required to limit chronic oral carriage of Candida albicans in transgenic mice expressing human immunodeficiency virus type 1. Infect Immun 74: 2382-2391.
41. Cutler JE, Poor AH (1981) Effect of mouse phagocytes on Candida albicans in in vivo chambers. Infect Immun 31: 1110-1116.
42. Redmond HP, Shou J, Gallagher HJ, Kelly CJ, Daly JM (1993) Macrophage-dependent candidacidal mechanisms in the murine system. Comparison of murine Kupffer cell and peritoneal macrophage candidacidal mechanisms. J Immunol 150: 3427-3433.
43. Sawyer RT (1990) Experimental pulmonary candidiasis. Mycopathologia 109: 99-109.
44. Sawyer RT, Garner RE, Hudson JA (1992) Effect of lectins on hepatic clearance and killing of Candida albicans by the isolated perfused mouse liver. Infect Immun 60: 1041-1046.
45. Marodi L, Korchak HM, Johnston RB Jr. (1991) Mechanisms of host defense against Candida species. I. Phagocytosis by monocytes and monocyte-derived macrophages. J Immunol 146: 2783-2789.
46. Baghian A, Lee KW (1988) Role of activated macrophages in resistance to systemic candidosis. J Leukoc Biol 44: 166-171.
47. Bistoni F, Vecchiarelli A, Cenci E, Puccetti P, Marconi P, et al. (1986) Evidence for macrophage-mediated protection against lethal Candida albicans infection. Infect Immun 51: 668-674.
48. Qian Q, Jutila MA, Van Rooijen N, Cutler JE (1994) Elimination of mouse splenic macrophages correlates with increased susceptibility to experimental disseminated candidiasis. J Immunol 152: 5000-5008.
49. Garner RE, Kuruganti U, Czarniecki CW, Chiu HH, Domer JE (1989) In vivo immune responses to Candida albicans modified by treatment with recombinant murine gamma interferon. Infect Immun 57: 1800-1808.
50. Lee KW, Balish E (1983) Systemic candidosis in silica-treated athymic and euthymic mice. Infect Immun 41: 902-907.
51. Rogers TJ, Balish E (1977) The role of activated macrophages in resistance to experimental renal candidiasis. J Reticuloendothel Soc 22: 309-318.
52. Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238-249.
53. Okayasu I, Hatakeyama S, Yamada M, Ohkusa T, Inagaki Y, et al. (1990) A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology 98: 694-702.
54. Fu Y, Ibrahim AS, Sheppard DC, Chen YC, French SW, et al. (2002) Candida albicans Als1p: An adhesin that is a downstream effector of the EFG1 filamentation pathway. Mol Microbiol 44: 61-72.
55. Rocha CR, Schroppel K, Harcus D, Marcil A, Dignard D, et al. (2001) Signaling through adenylyl cyclase is essential for hyphal growth and virulence in the pathogenic fungus Candida albicans. Mol Biol Cell 12: 3631-3643.
56. Marcil A, Harcus D, Thomas DY, Whiteway M (2002) Candida albicans killing by RAW 264.7 mouse macrophage cells: Effects of Candida genotype, infection ratios, and gamma interferon treatment. Infect Immun 70: 6319-6329.
57. Bendel CM, Hess DJ, Garni RM, Henry-Stanley M, Wells CL (2003) Comparative virulence of Candida albicans yeast and filamentous forms in orally and intravenously inoculated mice. Crit Care Med 31: 501-507.
58. Gale CA, Bendel CM, McClellan M, Hauser M, Becker JM, et al. (1998) Linkage of adhesion, filamentous growth, and virulence in Candida albicans to a single gene, INT1. Science 279: 1355-1358.
59. Kim AS, Garni RM, Henry-Stanley MJ, Bendel CM, Erlandsen SL, et al. (2003) Hypoxia and extraintestinal dissemination of Candida albicans yeast forms. Shock 19: 257-262.
60. Van Rooijen N, Sanders A (1994) Liposome mediated depletion of macrophages: Mechanism of action, preparation of liposomes and applications. J Immunol Methods 174: 83-93.
61. Badell E, Oeuvray C, Moreno A, Soe S, van Rooijen N, et al. (2000) Human malaria in immunocompromised mice: An in vivo model to study defense mechanisms against Plasmodium falciparum. J Exp Med 192: 1653-1660.
62. Lyczak JB, Pier GB (2002) Salmonella enterica serovar typhi modulates cell surface expression of its receptor, the cystic fibrosis transmembrane conductance regulator, on the intestinal epithelium. Infect Immun 70: 6416-6423.
63. Cryz SJ Jr., Furer E, Germanier R (1983) Passive protection against Pseudomonas aeruginosa infection in an experimental leukopenic mouse model. Infect Immun 40: 659-664.
64. Czuprynski CJ, Brown JF, Wagner RD, Steinberg H (1994) Administration of antigranulocyte monoclonal antibody RB6-8C5 prevents expression of acquired resistance to Listeria monocytogenes infection in previously immunized mice. Infect Immun 62: 5161-5163.